The Efficacy and Tolerability of Mebeverine in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials

Mokhtare, Marjan; Boghratian, Amirhossein; Agah, Shahram; Sheikhvatan, Mehrdad

doi:10.1016/s0016-5085(17)32503-9

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peppermint oil also inhibits smooth muscle contraction through calcium channel blockade and has been proven to reduce IBS symptoms, being a safe and effective treatment for IBS [68]. Mebeverine, a spasmolytic without atropine-like side effects, has high efficacy for abdominal pain and reduction in daily defecation frequency, as well as an improvement in global well-being, with good tolerability with minor complications [69,70].…”

Section: Antispasmodic Drugsmentioning

confidence: 99%

Irritable Bowel Syndrome: News from an Old Disorder

Ferreira

Garrido

Castro-Poças

2019

GE Port J Gastroenterol

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, which can affect all members of a society, regardless of age, sex, race or socioeconomic status. Because of its high prevalence and chronic nature, it represents a significant economic burden. In fact, these patients have a relevant impairment of their quality of life, which limits their work productivity and daily social activities, especially when it is associated with other disorders, such as anxiety and depression. The diagnosis of IBS relies on symptom-based diagnostic criteria with normal results on a limited number of complementary tests that rule out other possible diagnoses. The aetiology of this condition is incompletely established. However, evidence suggests that it is a multifactorial disorder with several different mechanisms that have been implicated as responsible for the symptoms. Since the treatment strategy is usually based on predominant symptoms and their severity, it is important to recognise the underlying mechanisms in order to successfully relief the visceral pain and altered bowel habits. The aim of this non-systematic review of the literature was to explore the pathophysiology and treatment options of IBS, highlighting the most recent evidence, from the new Rome IV criteria to the new drug armamentarium. Síndrome do intestino irritável: novidades de uma doença antiga Palavras ChaveSíndrome do intestino irritável · Revisão · Critérios Rome Resumo A síndrome do intestino irritável é um distúrbio gastrointestinal funcional, que pode afetar todos os membros da sociedade, independentemente da idade, sexo, raça ou estrato socioeconómico. Devido à sua elevada prevalência e natureza crónica, representa um encargo económico significativo. De facto, estes doentes apresentam uma alteração relevante da sua qualidade de vida, o que limita a sua produtividade laboral e atividades de vida diárias, sobretudo quando está associada a outros distúrbios, tais como ansiedade e depressão. O diagnóstico da síndrome do intestino irritável depende de critérios diagnósticos baseados em sintomas, com resultados normais num número limitado de testes complementares que exluem outros diagnósticos possíveis. A etiologia desta doença não está completamente estabelecida. No entanto, a evidência sugere que se trata de um distúrbio multifatorial com vários mecanismos diferentes que têm sido implicados como responsáveis pelos sintomas. Visto que a estratégia terapêutica é geralmente baseada nos sintomas predominantes e sua gravidade, é importante reconhecer os mecanismos subjacentes para aliviar com sucesso a dor visceral e a alteração dos hábitos intestinais. O objetivo desta revisão literária não sistemática consistiu em explorar a fisiopatologia e opções terapêuticas disponíveis para a síndrome do intestino irritável, realçando a evidência mais recente, desde os novos critérios Roma IV até ao novo arsenal farmacológico.

show abstract

Section: Antispasmodic Drugsmentioning

confidence: 99%

Irritable Bowel Syndrome: News from an Old Disorder

Ferreira

Garrido

Castro-Poças

2019

GE Port J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The primary endpoint is the change of JPAC-QOL from baseline to 2 weeks with magnesium oxide vs naldemedine intervention. JPAC-QOL consists of 28 questions assessed using a five-point adjectival score from 1-5, with a lower score indicating a better outcome for QOL (table 2) [22][23][24] and is shown to have acceptable reliability and validity to be used for psychometric evaluation in patients complaining of functional constipation [25].…”

Section: Study Endpointsmentioning

confidence: 99%

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: A proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study

Ozaki

Kessoku

Iwaki

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Patients taking opioids are known to develop opioid-induced constipation (OIC), which reduces their quality of life (QOL). The aim of this study is to compare magnesium oxide to naldemedine and determine which is more effective in preventing OIC. Methods: This is a proof of concept, prospective, randomized controlled trial, that commenced in Japan in March 2018. Initially, a questionnaire-based survey will be conducted targeting adult cancer patients who had concomitantly commenced opioid and OIC prevention treatment. Patients will then be randomly allocated to magnesium oxide (500 mg, thrice daily) or naldemedine (0.2 mg, once daily) groups. Each drug will be orally administrated for 12 weeks. The primary endpoint is defined as any improvement in the Japanese version of Patient Assessment of Constipation Quality of Life (JPAC-QOL) scores from the baseline to 2 weeks of treatment. Discussion : The primary endpoint is changes in the JPAC-QOL scores from the baseline to 2 weeks of intervention. The key secondary endpoint will be changes in spontaneous bowel movements (SBMs) at 2 and 12 weeks of intervention. This study will determine whether magnesium oxide or naldemedine is more effective for the prevention of OIC. Trial registration: This trial is registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000031891). Registered March 25, 2018, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000036408.

show abstract

The Efficacy and Tolerability of Mebeverine in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials

Cited by 2 publications

References 0 publications

Irritable Bowel Syndrome: News from an Old Disorder

Irritable Bowel Syndrome: News from an Old Disorder

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: A proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study

Contact Info

Product

Resources

About